Cargando…

Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities

The United States Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) established the Real-Time Oncology Review (RTOR) pilot program in 2017 to streamline the review process for oncology drug applications with the applicant and the Agency agreeing upon a piecemeal strategy and tim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Catherine, Virparia, Riddhi, Mui, Eric T.-K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081281/ https://www.ncbi.nlm.nih.gov/pubmed/33913098 http://dx.doi.org/10.1007/s43441-021-00296-7

Ejemplares similares

Maximizing Regulatory Review Efficiency: The Evolution of the FDA OCE RTOR Pilot
por: Gao, Ya Grace, et al.
Publicado: (2022)

Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid
por: Algorri, Marquerita, et al.
Publicado: (2022)

Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017
por: Ramamoorthy, Anuradha, et al.
Publicado: (2018)

Assessment of New Molecular Entities Approved for Cancer Treatment in 2020
por: Smith, Claire E. P., et al.
Publicado: (2021)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development
por: Faucette, Stephanie, et al.
Publicado: (2017)

Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
por: Lin, Hui-Heng, et al.
Publicado: (2017)

Viral Oncology: Molecular Biology and Pathogenesis
por: Mui, Uyen Ngoc, et al.
Publicado: (2017)

2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016)

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?
por: Schuller, Yvonne, et al.
Publicado: (2018)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Radiation Oncology Device Approval in the United States and Canada
por: Beers, Craig A, et al.
Publicado: (2019)

Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities
por: Wood, Matthew D., et al.
Publicado: (2019)

Programming Entity framework.
por: Lerman, Julia, et al.
Publicado: (2012)

Programming Entity Framework
por: Lerman, Julia
Publicado: (2009)

Programming Entity Framework
por: Lerman, Julia
Publicado: (2010)

Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology
por: Kurtin, Sandra E., et al.
Publicado: (2020)

Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?
por: Saleem, Azeem, et al.
Publicado: (2014)

Contemporary oncology trials, drug approvals and the physician-patient relationship
por: Schnog, John-John B., et al.
Publicado: (2022)

Single-arm trials for domestic oncology drug approvals in China
por: Zhang, Hong, et al.
Publicado: (2023)

Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
por: Demirci, Ebru, et al.
Publicado: (2023)

Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities
por: Schotland, Peter, et al.
Publicado: (2018)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment
por: Ho, Cheryl, et al.
Publicado: (2022)

Oncology approvals in 2020: a year of firsts in the midst of a pandemic
por: Amiri-Kordestani, Laleh, et al.
Publicado: (2021)

Real-time Java programming: with the Java RTS
por: Bollella, Gregory, et al.
Publicado: (2009)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

Semantically linking molecular entities in literature through entity relationships
por: Van Landeghem, Sofie, et al.
Publicado: (2012)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

Programming Entity Framework: Code First
por: Lerman, Julia, et al.
Publicado: (2011)

ADAMO: Entity-Relationship programming system
por: Fisher, S M
Publicado: (1995)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

Interprofessional Education Curriculum for Medical Assistants in Radiation Oncology: A Single Institution Pilot Program
por: Sinha, Sumi, et al.
Publicado: (2021)

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”
por: Chabner, Bruce A.
Publicado: (2017)

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision
por: Zhang, Yuqi, et al.
Publicado: (2022)

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
por: Tateo, Valentina, et al.
Publicado: (2023)

Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
por: Ho, Cheryl, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0mc1kkk9auduh29sle3ueabno2